Literature DB >> 27889175

Inhibition of Adenylyl Cyclase in the Spinal Cord Alleviates Painful Diabetic Neuropathy in Zucker Diabetic Fatty Rats.

Hao Feng1, Guodong Lu1, Qingsong Li1, Zhonghao Liu2.   

Abstract

OBJECTIVES: Diabetic neuropathy is the most common complication of both type 1 and type 2 diabetes. In this study, we tested the hypotheses that impaired Gi protein expression/function in the spinal cord is associated with the development of painful neuropathy in people with type 2 diabetes and that reduction of cyclic adenosine monophosphate (cAMP) production by inhibiting adenylyl cyclase in the spinal cord can alleviate diabetic neuropathy.
METHODS: To this end, we examined the levels of cAMP, cAMP-dependent protein kinase (PKA) and cAMP response element-binding protein (CREB) in the spinal cord after the development of neuropathic pain in Zucker diabetic fatty (ZDF) rats with type 2 diabetes. We evaluated the effects of intrathecal injections of SQ22536, an adenylyl cyclase inhibitor, on mechanical allodynia and thermal hyperalgesia in rats with painful diabetic neuropathy.
RESULTS: We found that diabetic ZDF rats exhibited mechanical allodynia and thermal hyperalgesia, which are associated with enhanced cAMP production, increased PKA activation and elevated CREB phosphorylation in the spinal cord. Additionally, diabetic ZDF rats exhibited attenuated expression of Giα, but not Gsα, in the spinal cord. Furthermore, intrathecal administrations of SQ22536 dose-dependently alleviated mechanical allodynia and thermal hyperalgesia in diabetic ZDF rats and reduced cAMP production, PKA activation and p-CREB expression in the spinal cord.
CONCLUSIONS: Taken together, our study suggested that cAMP-mediated signalling in the spinal cord is likely critical for the development of painful neuropathy in people with type 2 diabetes.
Copyright © 2016 Canadian Diabetes Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Zucker diabetic fatty rats; adenylyl cyclase; adénylcyclase; diabetic neuropathy; douleur; moelle spinale; neuropathie diabétique; pain; rats Zucker obèses et diabétiques; spinal cord

Mesh:

Substances:

Year:  2016        PMID: 27889175     DOI: 10.1016/j.jcjd.2016.09.006

Source DB:  PubMed          Journal:  Can J Diabetes        ISSN: 1499-2671            Impact factor:   4.190


  6 in total

1.  Methylglyoxal and a spinal TRPA1-AC1-Epac cascade facilitate pain in the db/db mouse model of type 2 diabetes.

Authors:  Ryan B Griggs; Diogo F Santos; Don E Laird; Suzanne Doolen; Renee R Donahue; Caitlin R Wessel; Weisi Fu; Ghanshyam P Sinha; Pingyuan Wang; Jia Zhou; Sebastian Brings; Thomas Fleming; Peter P Nawroth; Keiichiro Susuki; Bradley K Taylor
Journal:  Neurobiol Dis       Date:  2019-02-23       Impact factor: 5.996

Review 2.  Obesity-Associated Neuropathy: Recent Preclinical Studies and Proposed Mechanisms.

Authors:  Raiza Bonomo; Sarah Kramer; Virginie M Aubert
Journal:  Antioxid Redox Signal       Date:  2022-05-23       Impact factor: 7.468

3.  Methylglyoxal Requires AC1 and TRPA1 to Produce Pain and Spinal Neuron Activation.

Authors:  Ryan B Griggs; Don E Laird; Renee R Donahue; Weisi Fu; Bradley K Taylor
Journal:  Front Neurosci       Date:  2017-12-06       Impact factor: 4.677

Review 4.  Peripheral Neuropathy Phenotyping in Rat Models of Type 2 Diabetes Mellitus: Evaluating Uptake of the Neurodiab Guidelines and Identifying Future Directions.

Authors:  Md Jakir Hossain; Michael D Kendig; Meg E Letton; Margaret J Morris; Ria Arnold
Journal:  Diabetes Metab J       Date:  2022-03-24       Impact factor: 5.893

Review 5.  Diet-Induced Rodent Models of Diabetic Peripheral Neuropathy, Retinopathy and Nephropathy.

Authors:  Inês Preguiça; André Alves; Sara Nunes; Pedro Gomes; Rosa Fernandes; Sofia D Viana; Flávio Reis
Journal:  Nutrients       Date:  2020-01-18       Impact factor: 5.717

Review 6.  Recent Advances in In-Vitro Assays for Type 2 Diabetes Mellitus: An Overview.

Authors:  Nazmina Vhora; Ujjal Naskar; Aishwarya Hiray; Abhijeet S Kate; Alok Jain
Journal:  Rev Diabet Stud       Date:  2020-12-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.